Global hemophilia
market is expected to reach USD 15.2 billion by 2024, according to a new report
by Grand View Research, Inc. Increasing need for diagnosis of the target
population in order to initiate prophylaxis treatment and supportive government
programs is expected to be the vital impact rendering driver.
The market
players are predicted to adopt strategies such as pipeline product development
and geographic expansion in underdeveloped and developing regions, such as
Middle Eastern and West African countries.
As of 2015,
federal bodies such as the World Federation Hemophilia have vast information
and treatment regulation in about 172 countries, of which 20 were added in
2013,including Nigeria, Togo, Mali, Zambia, Mauritania, and others.
Competitive pricing
strategy is a vital factor promoting market players’ growth over the forecast
period. For instance, Biogen launched Eloctate in 2014 in the U.S. at a lower
price than the existing vastly used drug Advate.
In depth research report on Hemophilia Market
Further Key Findings From the Study Suggest:
·
Hemophilia B is
expected to grow at a rapid rate of over 6.0% during the forecast period.
Higher emphasis on pipeline products with an extended half-life and increasing
incidence of hemophilia B affected patients are expected to be the prominent
growth factors.
·
On-demand
treatment dominated the segment over the forecast period and is expected to
contribute more than 50.0% by 2024. However, prophylaxis is expected to be the
fastest growing segment because of the requirement for better control of
bleeding episodes and growing financial assistance programs by healthcare
providers and industry players.
·
For instance,
Grifols has launched the “AlphaNine SD Copay Card” and “ALPHANATE Copay
Program” for immediate enrollment in prophylaxis treatment by patients.
·
On the basis of
therapy, gene therapy is expected to be the fastest growing segment as a result
of increasing R&D and innovations in the field. Furthermore, replacement
therapy is expected to witness lucrative growth due to the launch of extended
half-life versions of currently available drugs.
·
For instance,
Novo Nordisk is working on N8-GP, CSL Behring is working on CSL689 rVIIa-FP,
and Bayer is working on BAY 94-9027.These are expected to be commercially
available around 2017/2018. This is expected to improve treatment over the
forecast period thereby boosting growth.
·
Major market
players include Biogen, Novo Nordisk, Baxalta, Octapharma, CSL Behring, Pfizer,
Inc., and Bayer Healthcare. Most of the companies are actively involved in the
awareness and treatment programs launched by regional governments and
hemophilia associations. Majority of their products that are awaiting FDA
approval have extended therapeutic use in adults as well as children.
Grand View
Research has segmented the global hemophilia market on the basis of type,
treatment, therapy, and region.
Global Hemophilia Market by Type (USD
Million), 2013 - 2024
·
Hemophilia A
·
Hemophilia B
·
Hemophilia C
·
Others
Global Hemophilia Market by Treatment (USD
Million), 2013 - 2024
·
On-demand
·
Prophylaxis
Global Hemophilia Market Therapy(USD
Million), 2013 - 2024
·
Replacement
Therapy
·
Immune Tolerance
Induction Therapy
·
Gene Therapy
Hemophilia Market By Region (USD Million),
2013 - 2024
·
North America
·
U.S.
·
Canada
·
Europe
·
UK
·
Germany
·
Asia-Pacific
·
Japan
·
China
·
Latin America
·
Brazil
·
Mexico
·
Middle East and
Africa
·
South Africa
·
Saudi Arabia
Browse more research reports of this
category:
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting
company, registered in the State of California and headquartered in San
Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, the company offers market intelligence studies ensuring
relevant and fact-based research across a range of industries including
technology, chemicals, materials, healthcare and energy.
No comments:
Post a Comment